Facebook
Twitter
LinkedIn
Forward
Best Practices in the Management of Oligometastatic and Oligoprogressive Liver Metastases
There are many effective liver-directed loco-regional therapies for limited liver metastases including advanced techniques/approaches in surgery, radiation therapy, and interventional radiology. Failure to stay informed leads to potential missed opportunities for offering the best types, sequences of liver directed therapies that ultimately provide the most optimal loco-regional control, quality of life for our patients with limited liver metastases from various cancer types.
As cancer patients continue to live longer with better systemic therapy, local-regional management of liver metastases with surgery, radiation therapy and interventional radiological approaches have become more impactful in improving patient longevity and quality of life. Given the various tools in each of our "toolboxes" currently, an optimally orchestrated and unified approach within these three disciplines is critical for achieving the best outcomes for loco-regional control for liver metastases. This activity explores this in depth with world-class experts educating learners on best evidence-based approaches utilizing a case-based, practical discussion format.
Topics:
- Management of Oligometastatic Disease to the Liver
Gagandeep Singh, MD, FACS - Interventional Radiological Techniques for Oligometastatic Liver Disease
Jared A. Christensen, MD - Vision Meets Precision: Advances in Radiotherapy for Liver Metastases
Erqi Pollom, MD, MS - Case Discussion/Q and A
Percy Lee, MD, FASTRO - Moderator
Full Panel
This activity is available from February 18, 2025, through 11:59 p.m. Eastern time on February 17, 2027.
The content was originally presented and recorded at the 2024 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, radiation therapists, dosimetrists, residents, liver surgeons and interventional radiologists.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Articulate when it is most appropriate to resect, radiate/ablate, or use interventional radiological approaches for local or local-regional spread of metastases in the liver.
- Determine the best sequence of use for these treatment modalities when used sequentially or concurrently to address oligometastatic or oligoprogressive liver metastases.
- Discuss the pros and cons of each of these liver-directed approaches in a multidisciplinary “tumor board” setting for a patient with liver-confined metastases in the liver.
- Percy Lee, MD, FASTRO, is employed by Lennar Foundation Comprehensive Cancer Center, City of Hope National Medical Center. Dr. Lee receives grant/research funding, honoraria and travel expenses from Viewray, Inc. Dr. Lee receives honoraria from Varian, Inc., AstraZeneca, Genentech and the RTOG Foundation. Dr. Lee is a member of the Radiosurgery Society Board of Directors.
- Erqi Pollom, MD, MS, is employed by Stanford University School of Medicine. Dr. Pollom receives honoraria from Vysioneer and Varian. Dr. Pollom receives compensation/payment from GT Medical Technologies.
- Jared Christensen, MD, is employed by University of Michigan.
- Gagandeep Singh, MD, FACS, is employed by City of Hope Los Angeles.
The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until February 17, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.